Inventor · disambiguated record
Liangxing Wu
Also filed as: WU LIANGXING
111 granted patents·58 pending applications·1,594 citations·filing 2009–2025
99Inventor score
Files withINCYTE CORP164SYNNOVATION THERAPEUTICS INC3CANCER RES INITIATIVES FOUNDATION1PIKAVATION THERAPEUTICS INC1
Top patents by PatentIndex Score
169 records- 0199US11566026B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jan 31, 2023·16 cites·19 claims
- 0298US11866435B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Granted Jan 9, 2024·7 cites·21 claims
- 0398US11787793B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Granted Oct 17, 2023·9 cites·25 claims
- 0498US11718605B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 8, 2023·11 cites·28 claims
- 0598US11673883B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·12 cites·29 claims
- 0698US11613536B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2021·Granted Mar 28, 2023·15 cites·15 claims
- 0798US11608337B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Mar 21, 2023·15 cites·22 claims
- 0898US11572366B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Feb 7, 2023·15 cites·28 claims
- 0998US11465981B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Oct 11, 2022·18 cites·28 claims
- 1098US11414433B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 16, 2022·23 cites·50 claims
- 1198US11407749B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 9, 2022·23 cites·24 claims
- 1298US11401279B2Pyrido[3,2-d]pyrimidine compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 2, 2022·24 cites·14 claims
- 1398US11339149B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted May 24, 2022·24 cites·20 claims
- 1498US11173162B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted Nov 16, 2021·22 cites·19 claims
- 1598US11124511B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Sep 21, 2021·28 cites·35 claims
- 1698US11053246B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Jul 6, 2021·23 cites·10 claims
- 1798US11014923B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted May 25, 2021·22 cites·32 claims
- 1898US10947230B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2019·Granted Mar 16, 2021·26 cites·44 claims
- 1998US10906920B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Feb 2, 2021·29 cites·41 claims
- 2098US10800768B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 13, 2020·30 cites·18 claims
- 2198US10793565B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 6, 2020·27 cites·16 claims
- 2298US10738048B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Aug 11, 2020·28 cites·21 claims
- 2398US10669271B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Jun 2, 2020·40 cites·20 claims
- 2498US10632126B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Apr 28, 2020·27 cites·8 claims
- 2598US10308644B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Granted Jun 4, 2019·115 cites·16 claims
- 2698US10131667B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2017·Granted Nov 20, 2018·35 cites·16 claims
- 2798US9801889B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2017·Granted Oct 31, 2017·40 cites·35 claims
- 2898US9758523B2Triazolopyridines and triazolopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Sep 12, 2017·21 cites·14 claims
- 2998US9695167B2Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·33 cites·41 claims
- 3098US9611267B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2013·Granted Apr 4, 2017·54 cites·4 claims
- 3198US9580423B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Feb 28, 2017·42 cites·31 claims
- 3298US9533984B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2014·Granted Jan 3, 2017·42 cites·6 claims
- 3397US11840534B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 12, 2023·4 cites·15 claims
- 3497US11667635B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2021·Granted Jun 6, 2023·7 cites·22 claims
- 3597US11535615B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Dec 27, 2022·9 cites·21 claims
- 3697US10851105B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Dec 1, 2020·27 cites·27 claims
- 3797US10618916B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Apr 14, 2020·31 cites·16 claims
- 3897US10251892B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2017·Granted Apr 9, 2019·33 cites·1 claims
- 3997US10214528B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2018·Granted Feb 26, 2019·35 cites·20 claims
- 4097US10138249B2Triazolopyridines and triazolopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Nov 27, 2018·15 cites·21 claims
- 4197US9944647B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted Apr 17, 2018·30 cites·12 claims
- 4297US9890156B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Feb 13, 2018·40 cites·8 claims
- 4397US9708318B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Jul 18, 2017·44 cites·41 claims
- 4497US9493442B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Nov 15, 2016·30 cites·47 claims
- 4596US11447494B2Tricyclic amine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Sep 20, 2022·8 cites·41 claims
- 4696US11427567B2Imidazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Aug 30, 2022·8 cites·22 claims
- 4796US11066404B2Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitorsINCYTE CORP·Filed 2019·Granted Jul 20, 2021·13 cites·24 claims
- 4896US10300051B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted May 28, 2019·14 cites·35 claims
- 4996US9994546B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted Jun 12, 2018·19 cites·12 claims
- 5096US9670210B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jun 6, 2017·23 cites·16 claims
Showing the top 50 of 169 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Liangxing Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →